The rating agency expects margins to weaken in 2026 as abundant capacity and softer rates erode underwriting profitability, though capitalisation will remain strong.
The rating agency also revised the outlook to stable, from positive, with the Chinese health insurer demonstrating a very strong balance sheet and steady investment income.